Best Microdosing GLP-1 Program in 2026: Real Prices, Real Picks, and Who Each One Fits
Published:
⚠ FDA regulatory update — April 30, 2026
The FDA proposed permanently closing the 503B bulk-substance compounding pathway for semaglutide, tirzepatide, and liraglutide. Most articles ranking for this search haven't caught up yet. We explain what it actually means for you below. Public comment period closes June 29–30, 2026. Proposal not yet final.
The best microdosing GLP-1 program for most people in 2026 is Gala GLP-1. Their microdose program lists at $149/month on a yearly subscription plan (Gala's FAQ separately notes that 3-month plans start at $199/month — final price set at checkout). Gala covers all 50 states through its provider network, prescribes compounded GLP-1/GIP including tirzepatide, and includes provider messaging and dose adjustments at no extra cost.
But the right pick depends on what matters most to you. Eden is the best flat-rate broad default — $149 first month then $249/month (or $129 first month on a 3-month plan), same price across every dose. bmiMD posts the lowest published microdose-specific pricing — $99/month for compounded semaglutide on a 12-month plan. SHED runs a compounded microdose injectable program from a brand built around needle-conscious dosing. And if you want FDA-approved medication or possibly insurance, Ro is the cleanest alternative.
| Best for | Pick | Starting price |
|---|---|---|
| Best overall microdose program | Gala GLP-1 | $149/mo on yearly plan ($199/mo on 3-month plan per FAQ) |
| Best flat-rate broad default | Eden | $149 first month → $249/mo (flat across all doses) |
| Best lowest published price | bmiMD | From $99/mo on 12-month plan ($1,188 upfront) |
| Best microdose injectable brand | SHED | From $149/mo sema; $199/mo tirz (2-mo minimum) |
| FDA-approved alternative | Ro | $39 first mo → $149/mo + medication priced separately |
Public-page check: May 8, 2026. Compounded medications listed on this page are not FDA-approved finished drug products.
The Quick Verdict — Best Microdosing GLP-1 Program by What You Need
The answer in one line: For most cash-pay shoppers who want a real microdose program from a clinician-led platform, the best microdosing GLP-1 program is Gala GLP-1. The right pick changes if your top priority is dose-flat pricing, the cheapest published number, a microdose-conscious brand, or FDA-approved medication.
You want a clean, midlife-friendly microdose program with broad reach → Gala GLP-1
$149/month on a yearly plan ($199/month on a 3-month plan per Gala’s FAQ)
You want a recognizable telehealth name with the same price across every dose → Eden
$149 first month then $249/month ongoing
You want the lowest published microdose-specific price → bmiMD
$99/month for compounded semaglutide on a 12-month plan
You want a brand built around microdosing as a philosophy → SHED
$149/month sema or $199/month tirz with a 2-month minimum
You want FDA-approved medication and possibly insurance help → Ro
$39 first month → as low as $74/month annual prepay, medication priced separately
If none of those fit cleanly, the matching quiz takes 60 seconds and points you to the right one based on your BMI, budget, state, and side-effect history.
Take the free 60-second matching quiz →What Microdosing GLP-1 Actually Means (and What Most People Get Wrong)
Microdosing GLP-1 means using a smaller-than-standard dose of a GLP-1 medication — usually under a clinician's care — to feel fewer side effects, lose weight more slowly, or save money. It is not an FDA-approved category. It's an off-label use of medications like semaglutide and tirzepatide.
It’s a dosing approach, not a separate drug category
Microdosing involves the same kinds of GLP-1 medications you’ve heard of. Some clinicians microdose by holding a lower FDA-approved titration step longer. Many online microdose programs prescribe compounded semaglutide or tirzepatide. Compounded GLP-1s are not FDA-approved finished drug products.
It’s not officially recognized
Tufts Medicine puts it plainly: there are no established clinical guidelines supporting GLP-1 microdosing as a weight-loss strategy, and the term itself is not formally recognized in clinical practice. (Source: Tufts Medicine, April 2026)
It’s not the same as splitting your own pen
Click-counting your own Ozempic or Wegovy pen is widely flagged as unsafe. Cleveland Clinic and GoodRx both warn against unsupervised dose stretching. Supervised microdosing through a licensed provider with a state-licensed pharmacy is a different thing entirely. (Sources: Cleveland Clinic, August 2025; GoodRx, December 2025)
Three reasons people search for it
- 1
Side effects
Standard starting doses cause nausea, constipation, or vomiting in many patients. Lots of people quit before they ever get to a useful dose.
- 2
Cost
Brand-name GLP-1s can run more than $1,000/month without insurance. Microdose programs run $99–$249/month.
- 3
“Food noise”
Some patients say they don’t want big weight loss — they just want the constant food-thoughts to quiet down.
How providers define microdosing differently
| Provider | How they describe it | Medication type | Plan basis |
|---|---|---|---|
| Gala GLP-1 | Lower-dose tirzepatide under a long-term wellness protocol | Compounded GLP-1/GIP | Yearly subscription for $149/mo; 3-month plan from $199/mo |
| bmiMD | Dedicated microdose page for sema and tirz | Compounded sema or tirz microdose | Plan-based, 12-mo cheapest |
| SHED | Microdose program with sema and tirz options | Compounded injectable | 2-month minimum |
| Noom | “25% or less of standard maintenance dose” (per their CMO) | Lower-dose GLP-1; 0.2 mg → 0.6 mg titration published | Initial 3–4 wk subscription, then $199/mo |
| Ro | Slow-titration of FDA-approved medications | FDA-approved Wegovy, Zepbound, Foundayo, Ozempic | Membership + medication priced separately |
Every program defines “microdose” a little differently. That's why comparing the price alone misses the point — you have to look at what they actually prescribe and how.
The Microdose Match Matrix — Every Program, Side by Side
We compared 8 microdose-relevant GLP-1 programs across the things that matter at checkout. Public-page check on .
| Program | Microdose page? | Lowest stated monthly | Plan basis | Medication type | Support model | 50 states? | Notes |
|---|---|---|---|---|---|---|---|
| Gala GLP-1 Microdose | Yes | $149/mo | Yearly; FAQ also refs $199/mo on 3-month plan | Compounded GLP-1/GIP (incl. tirzepatide) | Licensed provider, async messaging, app tracking, dose adjustments at no extra cost | Yes (per FAQ) | Final price set at checkout. Standard GLP-1/GIP listed at $179/mo on homepage. |
| Eden | No (flat-rate supports it in practice) | $129 first mo (3-mo plan) / $149 first mo → $249/mo ongoing | First month + ongoing | Compounded sema & tirz; brand-name optional | Provider access, ongoing | Provider-stated; verify at intake | Same price across every dose ongoing |
| bmiMD Semaglutide Microdose | Yes | $99/mo on 12-mo plan | $1,188 upfront on 12-mo; $129/mo month-to-month | Compounded semaglutide microdose | Telehealth visit, unlimited provider messaging, 24/7 support | Yes (per provider page) | Lowest published microdose-specific monthly requires 12-mo commitment |
| bmiMD Tirzepatide Microdose | Yes | $139/mo on 12-mo plan | $1,668 upfront on 12-mo; $179/mo month-to-month | Compounded tirzepatide microdose | Same as sema plan | Yes (per provider page) | One of the lowest published tirzepatide microdose prices in the category |
| SHED Microdose | Yes | $149/mo sema; $199/mo tirz | 2-month minimum | Compounded injectable sema or tirz | Provider access | Provider-stated; verify at intake | Microdose page is injectable. Broader SHED brand includes separate oral/sublingual products on other pages. |
| Noom Microdose GLP-1Rx | Yes | $79 intro 3–4 wk subscription, then $199/mo | Subscription | Lower-dose GLP-1; 0.2 mg → 0.6 mg titration published | 24/7 messaging, coaching, GLP-1 Companion app | Not in all states (per Noom) | Strongest coaching layer in the category; ongoing cost runs higher than competitors |
| MEDVi | Broad menu supports microdose-style starting | Verify at intake | Verify at intake | Compounded sema & tirz; multiple formats | Provider access, no membership fee | Provider-stated; verify at intake | ⚠️ FDA warning letter dated February 20, 2026 for marketing claims. See disclosure section below. |
| Ro (FDA-approved alternative) | No (slow-titration of brand-name) | $39 first mo → $149/mo (or $74/mo annual prepay) + medication | Membership + medication priced separately | FDA-approved Wegovy, Zepbound, Foundayo, Ozempic | Insurance concierge, free coverage checker | Yes | Cleanest path if you want FDA-approved instead of compounded |
Advertised Price vs. What You'll Actually Pay First
The lowest advertised number on the homepage is rarely the number you pay first. Multi-month plans show their per-month price upfront but bill the whole plan at once. This table shows both numbers side by side so you can budget honestly.
| Program | Lowest advertised monthly | What you may actually pay first | Why it matters |
|---|---|---|---|
| Gala GLP-1 microdose | $149/mo (yearly) / $199/mo (3-mo per FAQ) | Verify at checkout — Gala says final pricing is set at checkout | Two plan bases, two different real first charges — confirm yours before paying |
| bmiMD semaglutide microdose | $99/mo on 12-mo plan | $1,188 upfront for the 12-mo plan, or $129 if monthly | The $99 number requires the year-long commitment |
| bmiMD tirzepatide microdose | $139/mo on 12-mo plan | $1,668 upfront for the 12-mo plan, or $179 if monthly | Same structure — best price = longest commitment |
| SHED microdose semaglutide | $149/mo | 2-month minimum required | The 2-month floor is a softer commitment than annual but still a commitment |
| SHED microdose tirzepatide | $199/mo | 2-month minimum required | Same |
| Noom Microdose | $79 intro | $79 for first 3–4 weeks, then $199/mo for 12-week subscription | Real ongoing cost is $199/mo after intro |
| Eden | $129 first mo (3-mo plan) / $149 first mo otherwise | First month at discounted intro, then $249/mo | Flat across all doses ongoing |
| Ro Body | $39 first month | $39 first month membership + medication priced separately | Ro charges medication on top of membership |
Find Your Microdose Match — by Reader Profile
The best program changes based on your starting BMI, your priority, your state, and whether you're returning from a stalled full-dose attempt.
“I want a real microdose program from one trusted brand — and I'm done comparing”
→ Gala GLP-1. $149/month on a yearly plan, or $199/month on a 3-month plan per Gala's FAQ. They have a dedicated microdose program (not just a flat-rate page that allows microdosing in practice), they cover all 50 states through their provider network per their FAQ, they include provider messaging and dose adjustments at no extra cost, and they read midlife-friendly without being weight-loss-only.
“I want a recognizable telehealth name with one price across every dose”
→ Eden. $149 first month then $249/month — or as low as $129 first month on a 3-month plan per Eden's weight-loss page. The same price ongoing whether you're at a microdose strength or a full maintenance dose. That structure matters specifically for microdose searchers because staying low isn't a financial penalty.
“I want the lowest published microdose number, period”
→ bmiMD. $99/month for compounded semaglutide microdose on a 12-month plan ($1,188 upfront). $139/month for compounded tirzepatide microdose on the same plan ($1,668 upfront). bmiMD posts dedicated microdose product pages for both medications, lists pricing transparently, claims all-50-state coverage, and includes unlimited provider messaging and 24/7 support.
“I want a brand built around microdosing as a philosophy, not a checkbox”
→ SHED. SHED's microdose program runs $149/month for compounded semaglutide or $199/month for compounded tirzepatide, with a 2-month minimum commitment. The brand identity is built around using GLP-1s as a wellness and metabolic support tool rather than aggressive weight loss.
“I want FDA-approved medication, period”
→ Ro. Ro carries FDA-approved Foundayo (orforglipron, oral pill, FDA-approved April 1, 2026), Wegovy pill (FDA-approved December 2025), Wegovy pen, Zepbound pen, Zepbound KwikPen, and Ozempic. Ro Body runs $39 for the first month, then $149/month (or as low as $74/month with annual prepay). Medication is priced separately.
Gala GLP-1: The Best Overall Microdose Pick
Gala GLP-1 is our top pick for most cash-pay microdose searchers. The microdose program lists at $149/month on a yearly subscription plan; Gala's FAQ separately notes that 3-month GLP-1 plans start at $199/month, with final pricing set at checkout. Gala covers all 50 states through its provider network, prescribes compounded GLP-1/GIP including tirzepatide, and includes dose adjustments at no extra cost.
The price (read carefully)
Gala's homepage states microdosing GLP-1/GIP at $149/month based on a yearly subscription plan. Standard compounded GLP-1/GIP is $179/month on the same basis. Gala's FAQ then says GLP-1 treatment starts at $199/month with a 3-month plan, and that final pricing is set at checkout based on plan and medication selected. Confirm your exact line item at checkout before subscribing.
Who's behind it
Gala GLP-1 is a telehealth platform operated by AI Coaching, Inc. d/b/a Gala GLP-1. It connects you to licensed providers (including those affiliated with OpenLoop medical practices) and partner pharmacies. The Gala GLP-1 Tracker app is rated about 4.5/5 across roughly 390 reviews on iOS.
What's included
Provider review of your intake, prescription if appropriate, compounded GLP-1/GIP medication shipped to your door, async messaging with a licensed provider at no extra cost, and dose adjustments at no extra cost (per Gala's FAQ).
Important compliance note
Compounded medications are not FDA-approved finished drug products. Gala discloses this in its terms and on its homepage. The FDA has specifically warned companies against calling compounded GLP-1 the “same as Wegovy” or “the same as Mounjaro.” (Source: FDA, “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs,” 2026)
“I'm really happy with my GLP-1 journey so far. I'm steadily losing weight which feels encouraging and sustainable. The medicine arrives on time and the process is easy to follow. It has made a big dif…”— Verified Trustpilot review of Gala Health (2,000+ reviews as of May 2026). Individual results vary. Compounded GLP-1 outcomes are not guaranteed.
Who should NOT pick Gala
- You want true monthly billing with no commitment. The $149 microdose price requires the yearly plan; the 3-month plan starts at $199/month. Look at Eden instead.
- You want FDA-approved medication. Compounded GLP-1/GIP is not FDA-approved. Choose Ro instead.
Eden: Best Flat-Rate Broad Default
Eden's biggest selling point is dose-flat pricing — the same number whether you're at a microdose or a full maintenance dose. The semaglutide page shows $149 first month then $249/month; Eden's main weight-loss page shows compounded semaglutide as low as $129 first month on a 3-month plan.
Most GLP-1 platforms quietly raise your monthly price as you titrate. Eden doesn't. That structure matters specifically for microdose searchers, because it means staying low isn't a financial penalty.
What you get
- Compounded semaglutide and tirzepatide options
- Brand-name medication available too (Wegovy, Zepbound, Ozempic, Mounjaro) if you decide to switch
- Provider access and ongoing support
- HSA/FSA accepted
What you don't get
A page that markets itself as a “microdose” program. Eden's plan covers any dose under one number; the marketing emphasizes the flat-rate concept. Functionally, it's the same — your provider can prescribe a low starting dose and you can hold there as long as you and your clinician agree it's working.
bmiMD: Lowest Published Microdose-Specific Pricing
bmiMD posts the lowest microdose-specific published prices in the category — $99/month for compounded semaglutide on a 12-month plan ($1,188 total) and $139/month for compounded tirzepatide on the same plan ($1,668 total). The trade-off is the year commitment for the cheapest number.
bmiMD semaglutide microdose pricing
| Plan | Monthly | Total |
|---|---|---|
| 12-month | $99/mo | $1,188 upfront |
| 6-month | $109/mo | $654 total |
| 3-month | $119/mo | $357 total |
| Month-to-month | $129/mo | — |
Source: bmimd.com/glp-1-microdose, May 8, 2026
bmiMD tirzepatide microdose pricing
| Plan | Monthly | Total |
|---|---|---|
| 12-month | $139/mo | $1,668 upfront |
| 6-month | $149/mo | $894 total |
| 3-month | $159/mo | $477 total |
| Month-to-month | $179/mo | — |
Source: bmimd.com/glp-1-gip-microdose, May 8, 2026
“This company is legit! They were fast with sending out my shipment.”— bmiMD member testimonial published on bmimd.com/glp-1-microdose. Provider-published. Individual results vary.
Who should NOT pick bmiMD
- You want behavior coaching and habit-tracking tools. Noom has more of that.
- You want FDA-approved medication. Choose Ro.
- You want a midlife/menopause-positioned program. Gala is a better fit.
SHED: Best Microdose Injectable from a Needle-Conscious Brand
SHED runs a compounded microdose injectable program at $149/month for semaglutide or $199/month for tirzepatide, with a 2-month minimum commitment. The brand is built around using GLP-1s as a metabolic-support tool rather than aggressive weight loss.
Ro: The FDA-Approved Alternative
If the idea of a compounded medication makes you uneasy — or if you'd rather use insurance — Ro is the cleanest path. Ro Body costs $39 the first month, then $149/month ongoing (or as low as $74/month with annual prepay paid upfront). Medication is priced separately and includes FDA-approved Foundayo, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, and Ozempic.
Microdosing isn't only a compounded thing. With FDA-approved medications, the equivalent move is your clinician holding you at a lower titration step longer instead of climbing the standard ladder.
- FDA-approved medication (no compounding involved).
- An insurance concierge who handles prior authorization paperwork.
- A free GLP-1 Insurance Coverage Checker — type in your insurance, see what’s covered.
- Pricing that matches LillyDirect, NovoCare, and TrumpRx for medication.
Who should NOT pick Ro for microdosing
- You want a true sub-therapeutic dose like 0.05 mg semaglutide. FDA-approved medications aren't sold at those strengths.
- You're a cash-pay shopper trying to get under $200/month total. Compounded options will be cheaper.
Honorable Mentions and a Disclosure You Should Know About
A few programs come up often in microdose searches but aren't in our top picks. Here's why — and what you should know about each.
MEDVi
MEDVi runs a broad compounded GLP-1 menu with no membership fee, which makes it a popular choice for cash-pay shoppers. However, on February 20, 2026, the FDA issued MEDVi a warning letter citing two specific issues: (1) MEDVi's website displayed labels suggesting MEDVi was the compounder when in fact it was not, and (2) MEDVi's website made claims that its compounded products had the “Same active ingredient as Wegovy® and Ozempic®” and “Same active ingredient as Mounjaro® and Zepbound®” — language the FDA says implies its products have been FDA-approved when they have not. (Source: FDA Warning Letter to MEDVi, LLC dba MEDVi, MARCS-CMS 721455, February 20, 2026)
We're not including MEDVi as a top pick because that warning letter is fresh, public, and directly tied to the marketing-language standards we're using to evaluate every other provider on this page. If MEDVi later receives a close-out letter from the FDA confirming the issues were resolved, our position may change. Readers considering MEDVi should know about the warning letter and read it themselves before subscribing.
Noom
Noom Microdose GLP-1Rx starts at $79 for the initial 3–4-week subscription, then $199/month for a 12-week subscription thereafter. Noom states the program is not available in all states. The program includes 24/7 messaging with clinicians and care coordinators, a published 0.2 mg → 0.6 mg titration framework, the GLP-1 Companion app, and behavior coaching. If coaching and habit support matter as much to you as the medication itself, Noom has a stronger support layer than most microdose landing pages. The trade-off is that the ongoing cost runs higher than several microdose-specific cash-pay competitors. (Source: noom.com/med/glp1-microdose)
Maximus (entry-pricing — not yet a confirmed microdose program)
Maximus's marketing references low entry pricing across its broader weight-loss offerings, but the specific microdose program details and pricing weren't fully verified from official public pages during our review. We've removed Maximus from our ranked matrix until those details can be confirmed at checkout.
What the FDA's April 30, 2026 Proposal Means for You (Calmly)
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the regulatory list that lets large outsourcing facilities compound these drugs from raw ingredients. The proposal is not yet final. Public comment period closes June 29, 2026 per the FDA press release; the Federal Register notice lists comments due June 30, 2026. The proposal targets 503B bulk-substance compounding, not patient-specific 503A prescriptions, but it's worth understanding either way.
What changed
The FDA proposed closing the 503B bulk-compounding pathway for semaglutide, tirzepatide, and liraglutide. If finalized, large-scale 503B compounding from bulk substances ends.
What didn't change directly
503A patient-specific compounding operates under a separate framework that doesn't depend on the 503B Bulks List. State-licensed pharmacies can still fill an individual prescription. However, the FDA's shortage-related enforcement discretion ended for both 503A and 503B compounding earlier in 2025, and 503A pharmacies still face copy restrictions when an FDA-approved product is commercially available.
What you should do today
- 1Ask your provider whether your medication is dispensed by a 503A or 503B pharmacy.
- 2Ask whether they can switch you to FDA-approved medication if the regulatory landscape narrows.
- 3Don’t prepay for 12 months at a compounded program if you’re worried about disruption. The 3-month plan is a saner bet right now.
- 4If regulatory stability is your top priority, choose Ro and an FDA-approved medication.
Plain-English regulatory timeline
Is Microdosing GLP-1 Actually Safe?
Microdosing is off-label and not endorsed by major medical organizations. Lower doses may be easier for some people to tolerate, but side effects are still possible and standardized microdose safety/effectiveness data is limited. The bigger safety question is the program you choose — supervised microdosing through a licensed provider with a state-licensed pharmacy is materially different from click-counting a pen at home.
What we know
- Side effects (nausea, constipation, vomiting) are typically dose-dependent at standard escalation schedules. Lower doses may produce fewer, but side effects are still possible.
- As of July 31, 2025, the FDA reported 605 adverse-event reports for compounded semaglutide and 545 for compounded tirzepatide. Many cases involve dosing errors with multidose vials. (Source: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”)
- Even FDA-approved GLP-1s carry warnings: pancreatitis, gallbladder issues, possible thyroid C-cell tumors (boxed warning on some labels), severe GI events.
What we don't know
- Whether very low doses (0.05–0.1 mg semaglutide weekly) produce meaningful weight loss across most people. Trial data on microdose strengths is limited.
- Long-term safety at sub-therapeutic doses for non-diabetic, non-obese people using microdosing for “wellness” or “longevity.”
- Whether off-label microdose use produces the cardiovascular and renal benefits documented at trial doses. The trials studied trial doses.
What experts actually say
Cleveland Clinic obesity medicine specialist Dr. W. Scott Butsch: microdosing is fine when a clinician adjusts a prescribed dose for a specific patient — it's the unsupervised, click-counting, pen-stretching version that worries him. (Source: Cleveland Clinic Health, August 2025)
Tufts Medicine's Dr. Caitlin Polistena: there are no established clinical guidelines supporting microdosing as a weight-loss strategy. (Source: Tufts Medicine, April 2026)
How Microdose GLP-1 Dosing Actually Works
Microdose semaglutide schedules typically start at 0.05–0.125 mg per week (versus the FDA-approved Wegovy starting dose of 0.25 mg). Tirzepatide microdose schedules typically start at 0.5–1.0 mg per week (versus the FDA-approved Zepbound starting dose of 2.5 mg). Dose increases should be clinician-determined, not self-managed.
| Approach | Semaglutide | Tirzepatide |
|---|---|---|
| FDA-approved starting dose (standard label) | 0.25 mg once weekly (DailyMed Wegovy) | 2.5 mg once weekly for first 4 weeks (DailyMed Zepbound) |
| Compounded microdose programs (typical) | Start as low as 0.05–0.1 mg/week, hold 4–8 weeks, increase only as clinically appropriate | Start at 0.5–1.0 mg/week, hold longer than standard 4 weeks, increase slowly |
| Brand-name “microdose-style” approach | Provider holds you at 0.25 mg longer than standard schedule before escalating | Provider holds you at 2.5 mg longer than standard schedule before escalating |
What microdose programs should NOT do
- Have you split your own pen with click-counting.
- Ship you medication without a clinician evaluation.
- Increase your dose without provider approval.
- Quote a specific dose to you over a website intake form before a clinician reviews your case.
If a program is doing any of those, choose a different one.
Will a Smaller Dose Still Work for Weight Loss?
Some people lose weight on low doses; many lose less than they would at standard therapeutic doses. Standardized clinical evidence for microdosing as a weight-loss strategy is limited — published GLP-1 trials generally studied labeled or trial doses, not consumer microdose protocols.
The standard expectation gap is real
GLP-1 clinical trials (Wegovy, Zepbound, Mounjaro, Ozempic) studied specific dose ranges — generally not the microdose strengths used in consumer programs. Direct evidence for what 0.1 mg semaglutide weekly produces over 12 months in a typical patient is limited.
Adherence matters more than dose ceiling
Northwestern Medicine research has reported that 50–75% of patients who start standard-dose GLP-1s stop within a year. If a microdose helps you stay on the medication longer, total weight loss can end up higher than aggressive titration that quits at month 3.
Provider-stated outcomes vary
Each microdose program publishes different expectations. Treat provider-stated weight-loss numbers as marketing, not clinical evidence — and ask your clinician what’s reasonable for your specific situation.
Who tends to do well on microdose
- People sensitive to GI side effects
- People with smaller weight-loss goals (10–20 lbs)
- People returning after stalling on a full dose
- People primarily targeting “food noise” reduction
- Maintenance after standard-dose weight loss
Who probably needs a standard dose
- People who need to lose 30+ lbs for medical reasons
- People with type 2 diabetes targeting A1C reduction
- People who tolerated full doses well in the past and want maximum results
How Much Does a Microdose GLP-1 Program Actually Cost?
Verified microdose program prices in 2026 run from $99/month (bmiMD on a 12-month plan) to $249/month (Eden ongoing). The honest comparison isn't the lowest monthly number — it's the total first 90 days and the total first 12 months.
| Program | First 90 days | First 12 months |
|---|---|---|
| bmiMD semaglutide microdose (12-mo) | $297 (months 1–3 of $1,188 prepay) | $1,188 |
| bmiMD semaglutide microdose (monthly) | $387 ($129 × 3) | $1,548 |
| Gala GLP-1 microdose (yearly plan) | $447 (3 mo × $149 prorated; verify at checkout) | ~$1,788 |
| Gala GLP-1 microdose (3-mo plan per FAQ) | $597 ($199 × 3, verify at checkout) | ~$2,388 |
| SHED microdose semaglutide | ~$298 ($149 × 2 minimum, then $149 month 3) | ~$1,788 |
| SHED microdose tirzepatide | ~$398 ($199 × 2 minimum, then $199 month 3) | ~$2,388 |
| bmiMD tirzepatide microdose (12-mo) | $417 (months 1–3 of $1,668 prepay) | $1,668 |
| Noom Microdose | ~$676 ($79 first 4 wks + $597 next 12 wks) | ~$2,587 |
| Eden | $647 ($129 + $249 + $249 first 90 days) | ~$2,888 |
| Ro Body + medication | $39 + medication × 3 (verify medication price at intake) | $39 + 11 × $149 = $1,678 plus medication |
5 Microdose Program Red Flags (Walk Away If You See These)
We pulled these from FDA warning letters, court filings, and complaint patterns. Save this list.
They charge more as your dose goes up
A microdose program that bills you more when you titrate punishes the clinical guidance you’re paying them for. Look for flat pricing across all doses (Eden), plan-based pricing locked at signup (Gala, bmiMD), or transparent dose-adjusted pricing disclosed upfront. Avoid programs where you have to ask a support agent what happens if your dose changes.
They won’t tell you the pharmacy
Reputable 503A and 503B pharmacies are state-licensed and named. If a program won’t tell you which pharmacy fills your prescription, walk away. The FDA recommends you verify that compounded GLP-1 drugs come from a licensed pharmacy and are prescribed by a licensed health-care provider. (Source: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”)
They claim “same active ingredient” or “clinically proven” for compounded medication
The FDA has been actively enforcing this. The FDA has explicitly told companies they cannot describe non-FDA-approved compounded products as generic versions or the same as FDA-approved drugs, or claim they are clinically proven. MEDVi received a public warning letter on February 20, 2026 specifically for “Same active ingredient as Wegovy® and Ozempic®” claims. Programs that use this language haven’t read their own legal requirements.
They never assign you a real clinician
If your only contact with a clinician was a checkbox on the intake form, that’s not supervised microdosing. That’s mail-order vials with a forwarding address. The programs we feature on this page all include named provider access.
Their cancellation terms are vague or hidden
Search "[program name] cancel" on Reddit and Trustpilot before you sign up. Programs with auto-renewal traps, refund-fight patterns, or unclear policies will surface immediately. Confirm cancellation/refund terms with a screenshot before paying.
The 9-Question Checkout Checklist (Use This Before You Pay)
Before you click subscribe on any microdose GLP-1 program, you should be able to answer all nine of these questions out loud. If you can't, the program isn't transparent enough.
- 1
Is this compounded medication or FDA-approved medication?
- 2
What active ingredient will be prescribed? (semaglutide, tirzepatide, etc.)
- 3
Who reviews my intake? (Named licensed clinician, in your state.)
- 4
Which pharmacy fills my prescription? (State, license, name.)
- 5
What exactly will I be charged today? (Including any “shipping” or “supply” surcharge.)
- 6
What’s the recurring billing date? (And how is the next charge calculated?)
- 7
Can I cancel online without calling? (And if I cancel, do I get a refund for unused medication?)
- 8
What happens if my clinician decides I’m not eligible? (Refund? Routed to alternative? Charged anyway?)
- 9
What support do I have if side effects start? (Same-day messaging? Phone? Provider assigned?)
Microdose vs. FDA-Approved GLP-1: Which Path Is Right for You?
| Choose microdose compounded if… | Choose FDA-approved if… |
|---|---|
| You’re side-effect sensitive | You have insurance that may cover GLP-1s |
| You want a slower start than FDA labels allow | You want Wegovy, Zepbound, Ozempic, Mounjaro, or Foundayo specifically |
| Your weight-loss goal is 10–20 lbs | You have complex medical history |
| You prioritize cost | You’re worried about regulatory shifts in compounded |
| You’re maintaining after standard-dose loss | You want manufacturer-supervised quality |
| You’re comfortable with off-label use | You’re not comfortable with compounded products |
How We Picked These Programs (Methodology)
We reviewed public provider pages on . Our ranking is based on microdose program clarity (20%), pricing transparency including first-charge math (20%), clinical support (15%), compounded/FDA disclosure quality and active FDA actions (15%), state availability (10%), cancellation visibility (10%), and search-intent fit (10%). Affiliate payouts are used only as a tie-breaker when evidence and fit are comparable.
What we reviewed: Each provider's homepage, pricing page, FAQ, and any dedicated microdose program page. We also checked the FDA warning letter database for each featured provider on May 8, 2026.
What we cross-referenced: FDA press releases and the Federal Register notice published May 1, 2026; DailyMed labels for FDA-approved GLP-1 dosing schedules; FDA warning-letter database (MEDVi has an active warning letter dated February 20, 2026; no other featured provider had an active warning letter on May 8, 2026 from our public-page check); Trustpilot ratings for each featured provider.
What we did NOT do: Test long-term clinical outcomes. Test pharmacy-by-pharmacy potency variation. Verify final intake-completion checkout pricing, exact pharmacy assignment, or state-specific eligibility for individual readers.
What We Actually Verified (and What We Didn't)
Verified on from public provider pages and primary regulatory sources:
- Public pricing on each provider’s homepage and pricing page
- Whether each provider runs a microdose-specific program page
- Provider-stated support claims (provider messaging, dose-adjustment rules)
- Provider-stated state availability claims
- Compounded/FDA disclosure language on each page
- The FDA April 30, 2026 proposal text and Federal Register notice
- DailyMed labels for Wegovy and Zepbound dosing schedules
- FDA warning letter database for each featured provider (MEDVi: active warning letter Feb 20, 2026; no active warning letters on other featured providers on May 8, 2026)
- Real customer reviews (Trustpilot for Gala; provider-published for bmiMD)
Not verified — confirm at checkout:
- Final checkout pricing (intake-completion specific)
- Pharmacy partner names for individual prescriptions (varies)
- State-specific prescribing edge cases for your state
- Whether plan pricing changes after dose adjustment (some providers; verify yours)
- Refund/cancellation specifics for your plan
We re-verify pricing and program details quarterly and after every FDA action on compounded GLP-1s.
Frequently Asked Questions
- What is the best microdosing GLP-1 program?
- The best microdosing GLP-1 program for most cash-pay shoppers is Gala GLP-1, listed at $149/month on a yearly subscription plan (or $199/month on a 3-month plan per Gala’s FAQ, with final pricing set at checkout). Eden wins for flat-rate dose-independent pricing, bmiMD for the lowest published microdose-specific pricing ($99/month on a 12-month plan), SHED for a microdose-conscious brand identity, and Ro for FDA-approved alternatives.
- Is microdosing GLP-1 FDA-approved?
- No. Microdosing is not an FDA-approved dosing strategy or drug category. The FDA has approved specific GLP-1 medications (like Wegovy, Zepbound, Ozempic, Mounjaro, and Foundayo) at specific dose ranges for specific indications. Microdosing is an off-label use.
- Are compounded microdose GLP-1 medications FDA-approved?
- No. Compounded medications are prepared by licensed pharmacies based on individual prescriptions and are not reviewed or approved by the FDA as finished drug products. Compounded products should not be described as “the same as” FDA-approved medications.
- How much does a microdose GLP-1 program cost?
- Verified 2026 microdose program prices range from $99/month (bmiMD on a 12-month plan, $1,188 upfront) to $249/month (Eden ongoing). Gala GLP-1’s microdose lists at $149/month on a yearly plan, with the FAQ separately referencing $199/month on a 3-month plan; final pricing is set at checkout. SHED runs $149/month for semaglutide and $199/month for tirzepatide with a 2-month minimum.
- Can you lose weight on a smaller GLP-1 dose?
- Some people do, particularly side-effect-sensitive patients and those targeting modest weight loss. Standardized clinical evidence for microdosing as a weight-loss strategy is limited — published GLP-1 trials generally studied labeled or trial doses, not consumer microdose protocols. Results are not guaranteed. Talk with your clinician about what’s reasonable for your situation.
- Who is microdosing GLP-1 best for?
- Side-effect sensitive patients, people with smaller weight-loss goals, people returning after stalling on a full dose, those primarily targeting “food noise” reduction, and patients in maintenance after standard-dose weight loss.
- Who should NOT choose microdosing GLP-1?
- People who need significant weight loss for medical reasons, people with type 2 diabetes targeting A1C reduction, people with complex medical histories who need close clinical supervision, and people who cannot verify the pharmacy and clinician behind a program.
- Is Gala GLP-1 legit?
- Yes. Gala GLP-1 is operated by AI Coaching, Inc., publishes clear pricing and disclosures, claims all-50-state availability through licensed providers, and discloses that its compounded medications are not FDA-approved finished drug products. Trustpilot shows 2,000+ customer reviews. As with any compounded program, verify pharmacy details and final checkout pricing before subscribing.
- Is bmiMD microdose legit?
- Yes. bmiMD posts dedicated semaglutide and tirzepatide microdose pages, publishes plan-based pricing, claims all-50-state availability, and includes telehealth visits, unlimited provider messaging, 24/7 support, and refunds if the clinician determines you are not eligible. Verify final checkout pricing and pharmacy partner before subscribing.
- Does MEDVi have an FDA warning letter?
- Yes. The FDA issued MEDVi a warning letter dated February 20, 2026, citing two issues: (1) MEDVi’s website displayed labels suggesting MEDVi was the compounder of its products when in fact it was not, and (2) MEDVi’s website made claims that its compounded products had the “Same active ingredient as Wegovy® and Ozempic®” — language the FDA says implies the products have been FDA-approved when they have not. Readers should review the warning letter before evaluating MEDVi.
- What does the FDA April 30, 2026 proposal mean for me?
- The FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The proposal targets large-scale 503B compounding from bulk substances, not patient-specific 503A prescriptions. The proposal is not yet final — comments are due June 29, 2026 per the FDA press release, or June 30, 2026 per the Federal Register notice. If regulatory stability is your priority, FDA-approved options through Ro are the cleanest path.
- Can I microdose Ozempic or Wegovy at home?
- No. Click-counting your own pen is widely considered unsafe by Cleveland Clinic and GoodRx. Pens are not designed to deliver fractional doses accurately. If you need a lower dose of an FDA-approved medication, ask your provider to hold you at a lower titration step longer rather than splitting doses yourself.
The Final Verdict
The best microdosing GLP-1 program in 2026 is Gala GLP-1 for most cash-pay shoppers — $149/month on a yearly plan ($199/month on a 3-month plan per Gala's FAQ, final pricing at checkout), all 50 states, compounded GLP-1/GIP including tirzepatide, dose adjustments at no extra cost.
The right pick changes if your priority is dose-flat pricing (Eden), the lowest published microdose-specific number (bmiMD), a microdose-conscious brand (SHED), or FDA-approved medication (Ro).
The wrong pick for everyone is a program that won't tell you the pharmacy, charges you more as your dose changes, or markets compounded products as the same as FDA-approved drugs. MEDVi received an FDA warning letter on February 20, 2026 specifically for that last problem. Read it before you subscribe.
If you read this whole page and you still want to start microdosing, you're not wrong for it. You're informed. Pick the program that fits your situation, run the 9-question checkout checklist before you click subscribe, and start the eligibility check.